Dramatic increases in overall childhood cancer survival since the 1970s are due, in part, to collaborative, prospective research. However, childhood cancer represents a mixture of cancer types with varying survival. Children with acute lymphocytic leukemia (ALL), germ cell tumors, or nephroblastoma are most likely to benefit from current medical technologies. Consistently curative treatment of other types of cancers such as bone-based malignancies or central nervous system tumors remains elusive. Mortality rates for these types of tumors were unchanged from 1996 to 2006. 1 Treating a child with cancer is an expensive and resource-intense proposition for the health care system and the families involved. Therapies for childhood cancer have mirrored or outstripped the rapid growth seen in the overall health care system. According to the Healthcare Cost and Utilization Project, the average charge of an admissions for pediatric cancer therapy increased by 36%, from $29 700 in 2000 to $40 400 in 2009 (2009 US dollar [USD]), greater than the 30% increase in other pediatric admissions during that same time. 2 Total inpatient and outpatient medical costs averaged ∼$19 000 per year per patient in a 1985 study 3 and closer to $51 000 per patient in the first year of treatment in a 1992 single institution review. 4 Analysis of total medical costs of treatment of children with leukemia or central nervous system tumors in 2004 estimated average costs of $89 000 for children who survived and $236 000 for those who died. 5 Families of children with cancer face out-of-pocket medical expenses, expenses for travel, and loss of income from time off of work; expenses that may exceed a family' s income. 6, 7 Increasing health care resource utilization and varied survival gains suggest that a portion of the increased utilization is not associated with improved outcomes. Economic evaluation (EE), or comparing treatments on the basis of monetary units, may provide decisionmakers with additional data to supplement medical-based outcomes. EE can estimatethemonetary valuesonly (costs analysis [CA] ) or relate the costs to an outcome such as survival or infection (cost effectiveness analysis [CEA] ), a user preference (cost utility analysis [CUA] ), or a willingness to pay for the treatment (cost benefit analysis [CBA] ). Such evaluations require resources to perform properly and can have limited generalizability across time, geographic borders, and health care systems. 8 These later limitations can be lessened by robust EE methodology. EEs consider the perspective of the decision-maker (medical system, patient, society) when deciding which components of treatment to include in the costs. 9 A treatment that is more cost effective for the hospital or third party payer is not necessarily more cost effective for the family, or may have significant late effects that affects the patient' s longterm productivity. 10 The object of this study was to identify and describe existing EE applied to childhood cancer therapies via a systematic review of the literature with hopes to instruct future research.
METHODS

Study Selection
Inclusion criteria for our systematic review required reports of original research using monetary units to comparing 2 or more tumor-directed or supportive measures for the treatment of childhood cancer. This review was limited to articles in the English language and originating from nations associated with the Organization for Economic Cooperation and Development. If an article included reports on both adults and children, it was included only if a childspecific EE was evident.
A structured literature search was performed of the Medline (Ovid), PubMed (National Library of Medicine), and the National Health Service EE databases from January 1, 2000, to December 31, 2011 . Concepts that made up the search included "cost analyses," "child," and "cancer." A complete list of search strategies can be found in Supplemental Appendix 1. The resulting abstracts were evaluated by the predefined inclusion and exclusion criteria first in abstract form and then in full-text format by a single reviewer (Dr Russell). When the reviewer questioned inclusion of an article, the research group decided via consensus.
Two reviewers (Drs Russell and Panchal) abstracted data from each article into an extraction spreadsheet according to their field of expertise. Information collected included patient population, outcomes, treatments under comparison, and whether these were tumordirected therapies (component of direct antitumor interventions with chemotherapy, radiation therapy, surgical procedures, or a combination) or supportive therapies (medications, surgical intervention, or processes designed to abrogate complications from tumor-directed therapies). The type of EE was captured and categorized as CA if it measured or valued treatments in monetary units without comparison with an outcome, a CEA if the monetary units were compared with a health outcome consequence, a CUA if the monetary units were compared with a patient/caregiver utility or value-based consequence, or CBA if results were presented as a willingness to pay for the therapy. Incremental cost effectiveness ratios, a measure of the additional cost for an additional successful outcome, were identified if included in the report. All monetary units were converted to 2012 USD by using the Consumer Price Index. 11 The exchange rate on June 30 of the original year was used to convert other currencies to USD. 12 If the article did not state the monetary unit's original year, the year before the year of publication was assumed. If a range of dates was presented, the midpoint year was chosen as the original year.
Descriptive features of the investigators were captured by identifying the country (or countries) of origin and research setting (single institution, multiple institution, or cooperative group). The perspective of the EE was captured according to the authors' stated definition or as "not stated." Data sources were categorized as retrospective or prospective medical and/ or research charts, hospital database for institution-based administrative database, and regional-national database for reimbursement or health care databases available to more than 1 institution. Descriptive statistics were performed by using Stata version 11 (Stata Corp, College Station, TX).
Qualitative Assessment of EEs
A quality assessment of the methodology was executed on included studies by utilizing the criteria provided by Drummond et al, 13 entitled "A check-list for assessing economic evaluations." This previously validated checklist 14 identifies 10 key elements and methodological characteristics users may expect to find in well-executed studies (Table 1) . Each item is scored as "yes," "no," or "can't tell," and a point is given for each "yes." A higher quality study was defined as a score $7. 14 A single reviewer (Dr Panchal), experienced in applying this tool, scored all the articles.
RESULTS
Search Results
Of the 854 citations identified, 40 met our inclusion criteria (Fig 1) . Most studies (24; 60%) were published in 2005 or earlier. European investigators performed the majority of the studies (n = 22, 55%) followed by investigators in the United States (n = 10, 25%) and Canada (n = 7, 17%). The intervention studies were varied but concentrated toward a few topics. Eleven studies addressed costs of tumor-directed therapies ( Table  2) ; 5 of these compared or described costs associated with hematopoietic stem cell transplantation. Twenty-nine articles compared costs of supportive therapies (Table 3) . Nine (31%) of these studies investigated costs associated with treatment of infections, 7 articles questioned the cost and/or benefits of adding granulocyte colony stimulating factor [G-CSF] to myelosuppressive chemotherapy, 3 articles studied the Was a comprehensive description of the competing alternatives given? 3.
Was the effectiveness of the programs or services established? 4.
Were all the important and relevant costs and consequences for each alternative identified? 5.
Were costs and consequences measured accurately in appropriate physical units? 6.
Were costs and consequences valued credibly? 7.
Were costs and consequences adjusted for differential timing? 8.
Was an incremental analysis of costs and consequences of alternatives performed? 9.
Was allowance made for uncertainty in the estimates of costs and consequences? 10.
Did the presentation and discussion of study results include all issues of concern to users? BM, bone marrow; DB, database; EFS, event free survival; ICER, incremental cost effectiveness ratio; LYG, life years gained; NA, not applicable; NS, not significant; Patient (P), study included prospectively gathered patient data; Patient (R), study included retrospective patient data; PBPC, peripheral blood progenitor cell.
a Currency not stated in year, assumed year before publication. potential for tailoring chemotherapy by genotyping, and the remaining 12 studies covered topics such as prevention or treatment of tumor lysis syndrome, antiemetic regimens, transfusions, and central venous catheter placement.
REVIEW ARTICLE
Economic Evaluations
Most studies compared treatments by using CA (26; 63%) as their EE. These CAs frequently have a clinical outcome reported but not included inthe comparison of costs. Fifteen studies (36%) performed CEA. One article included both a CEA and a CUA. 15 No CBA studies were identified.
A tabulation of each article' s Drummond score is contained in Supplemental Appendix 2. The median Drummond score for all studies was 6 (range, 2-9). Studies focusing on tumor-directed therapy scored higher with an average score of 7.18 compared with supportive therapy studies (average score, 5.3; P = .007). Most articles posed a well-defined question in answerable form (item 1) (n = 38, 95%), established the effectiveness of the programs or services (item 3) (n = 35, 88%), discussed the issues of concern to the users (item 10) (n = 35, 88%), and comprehensively described the competing alternatives (item 2) (n = 34, 85%). The most common categories resulting in a "no" or "can't tell" score were item 7, adjusted for differential timing (n = 34, 85%), item 8, performed incremental analysis of costs and consequences of alternatives (n = 31, 78%), item 6, credibly valued costs and consequence (n = 28, 70%), and item 9, allowed for uncertainty in the estimates of costs and consequences (n = 25, 63%).
An EE is meant to aid a decision-maker in choosing between 2 or more options. The perspective of the decision-maker, therefore, guides which inputs should be included in the cost estimate. We reviewed the articles for a statement of the intended perspective. Thirteen articles stated the perspective of the health care system, 8 focusing specifically on REVIEW ARTICLE the "hospital" perspective. Six described the perspective as including the family or societal costs. Twenty-one articles did not state the perspective of their EE.
The inputs and sources of data were capturedforeach analysis (Tables 2 and 3) . Two articles did not state the inputs considered in their EE. 16, 17 The majority of studies (n = 34, 85%) included data from a median of 55.5 (range, 12-719) patients' medical or research charts. Twenty-four (69%) of these studies used patient data from a single institution. Because patient medical or research records rarely contain the costs or charges of medical therapy, additional sources are required to identify monetary units to assign to each input. The most common additional sources used for single institution studies were the hospital administrative databases (n = 16, 67%) and regional or national databases (n = 9, 38%). The additional sources were not identified in 10 of the single institution studies (42%). Six studies modeled hypothetical patients from a combination of sources. Once inputs are identified in terms of monetary units, the "time" of the monetary unit provides a reference point for decision-makers when comparing across studies. The currency (USD, Canadian dollar, Euro, etc) was stated in all articles, but the time reference of that currency was only stated in 21 (53%) of the articles (n = 21).
Infection
Eight articles considered treatment (n = 7) or prevention (n = 1) of infection.
Three of these articles stated the health care system as the perspective of their EE, 15, 17, 18 and 1 stated both the health care system and the patient. 19 The 4 remaining articles did not state their perspective, input, or cost sources 16, [20] [21] [22] and were excluded from further comparison. Teuffel et al 15 modeled options for delivering antibiotics in the inpatient and outpatient setting for children with low-risk fever and neutropenia (F+N). They used repeat F+N episodes adjusted for family preference as a clinical end point. They estimated the costs of home intravenous (IV) antibiotics as $2866 per episode, and although brief admissions for IV antibiotics followed by home antibiotics was more effective, it was also more expensive ($5852 per episode) costing an additional $142 814 per repeat F+N episode prevented. Klaassen et al 18 estimated the costs of a brief hospitalization for F+N followed by discharge after randomization to antibiotics or placebo; their CEA analysis used readmission for infection as a clinical end point. Fewer readmissions occurred for patients receiving placebo resulting in an incremental saving of $189 per patient. 18 Santolaya et al 19 also compared the costs of continuing antibiotics at home or in the hospital, options similar to 2 of the 4 considered by Teuffel et al. 15 They estimated early discharge with antibiotics at home to cost less than continuing in the hospital ($797 vs $1128 per episode). This more cost effective option was similar to the option estimated to cost $5852 by Teuffel et al. 15 The sevenfold difference in total costs may reflect the health care systems performing the studies, Canadian versus Chilean.
Granulocyte Colony Stimulating Factor
Seven articles studied the incorporation of G-CSF into therapy. All EEs were cost analyses rather than CEA. Although only 2 articles expressly stated from the health care decisionmaker' s perspective in their EE, all 7 included direct medical costs of treatment consistent with that perspective. Ammann et al 23 compared schedules for repeating laboratories and discontinuing G-CSF and revealed individualized schedule saved $203 per patient over a standardized schedule. Three articles presented results of trials randomly assigning patients with leukemia to chemotherapy with or without G-CSF although the phase of leukemia treatment is different in each study limiting comparison of total costs between the studies. [24] [25] [26] Three additional studies compared the costs of including G-CSF after autologous hematopoietic stem cell transplant (SCT), 1 at the investigator' s discretion 27 and the others via randomization. 28, 29 There was no statistically significant difference between total costs in any of these 6 studies although G-CSF made a substantial contribution to costs if patients received it, whereas hospital costs were greater if G-CSF was not given (Table 4) . Gonzalez-Vincent [31] [32] [33] [34] The difference in total costs reported on these studies reflect, in part, the time horizon after transplant captured. Three articles included costs of graft acquisition and direct medical costs from admission to discharge from the transplant admission 32 or 1100 days. 31, 34 Average costs of a peripheral blood SCT on these studies are estimated as $10 891 32 and $19 514. 31 Majhail et al 34 39 Santolaya et al, 19 and Hancock-Howard et al 40 included both direct medical costs and family costs in their societal perspective. Kurre et al 39 used family diaries to collect expenses of patients with leukemia randomly assigned to pegaspargase or Escherichia coli asparaginase through induction and delayed intensification phases of chemotherapy. Travel, productivity, and lodging costs were ∼$3725 to $4648, ,10% of the total direct medical costs ($47 143-$48 084). 39 The treatment arm with higher family costs had lower total costs. Only 38% of patients were compliant with diaries by the end of the study. Santolaya et al 19 included family travel costs in their study comparing costs of early hospital discharge after F+N. Although estimated total costs were lower than other contemporary F+N reports as noted above, travel costs were ,5% of these costs. Finally, Hancock-Howard et al 40 estimated costs of venous access placement in a conventional operating room or interventional radiology. Productivity losses contributed 6.8% to 7.5% of total costs, and travel costs only 0.7% to 1.5%. 40 When family and direct medical costs are analyzed together, family costs were consistently a minor component of total costs. 26 and another that was published in 1997. 42 Barr et al' s 41 review focused on demonstrating the potential of utility measures into economic comparisons and may have not identified all of the published EEs. A structured review of publications on health-related quality of life and economic outcomes in ALL before 2000 failed to identify any comprehensive EE of treatment. 43 The increase in publications over the past decade suggests in increased application of EE methods. The predominance of single-institution studies and broad spectrum of treatment questions, especially supportive measures, found in our review suggests an individualist approach to EE research in this field.
The relative logistical ease of single institutional research over collaborative work and supportive therapy questions (ie, a short time line, a welldefined treatment and outcome) over more complicated cooperative group treatment regimens make such a direction more appealing to the researcher with limited resources.
We reviewed literature representative of medical management in the contemporary, economically developed health care systems. Our time frame of 2000 forward accounts for contemporary treatments, outcomes, and supportive decisions. Nations affiliated with the Organization for Economic Cooperation and Development are all considered high-income nations by the World Bank. 44 Health care systems from these nations could be expected to give technically similar therapies. But differences in organization and funding 44 pose challenges when applying treatment costs from 1 system to another or across time. Using a qualitative scoring system such as the Drummond Scale is 1 way to gauge the transferability of a study and its results. It is limited to the EE and does not address other aspects of the study such as medical merit or applicability in the new location. Other tools to assess all aspects of generalizability are under development 8 and all determine the quality of the EE. Scoring systems are limited by bias of the reviewer although interreviewer variability seems minimal. 14 This review helps to demonstrate the challenges associated with comparing results of EE studies when the quality of the EE is low. 14 Our distribution of individual categorical scoring is consistent with previous validation of this tool. Items 1, 2, 3, and 10 are almost always present, and item 7 (costs adjusted for differential timing) is almost never present. 14 Only half of the studies we reviewed stated a time reference for their costs estimates. Our use of the value the year before publication, which assumes that the authors adjusted all their costs within the study, may have resulted in an erroneous estimate of current value because inflation and exchange rates change with time. Studies that did not clarify the perspective of the EE prevented a clear assessment of whether all the costs were included, but studies that did not clarify what costs were included or where they derived their unit costs cannot be compared with other studies nor generalized outside of their institution. Correction of these reporting limitations in future EE would add significantly to the usefulness of the results to decision-makers.
EEs determine an estimate of cost around which there remains uncertainty because the design of the study and the parameters used within the study are not completely accurate. 45 Assessment of the impact of uncertainty, referred to as sensitivity analysis, is an important component of an EE but was included in only 37% of the studies. Very few studies identified a statistically significant difference between treatments under comparison. EE may require larger samples sizes than those needed to detect clinical difference, 46 ,47 so the low number of patients on the studies reviewed likely limited the success. Studies from multiple institutions or use of models may help produce more reliable results, although each of these solutions has its own limitations.
Four of our articles included family costs of transportation, productivity losses, and/or living expenses associated with the treatments being compared. When the EE included these costs in the total costs, the costs incurred by the families was ,10% of total costs and were unlikely to impact the overall cost differential. But if considered only from the perspective of the family, the costs could be substantial. In addition, the family costs estimated on these studies represents only a portion of all the family costs incurred during treatment of a child with cancer. 6, 48 A 2011 systematic literature review focusing on studies of family-incurred costs revealed that costs could reach .200% of annual income. 7 Similar to the EEs identified our study, methodological issues and limited research were significant limitations to understanding family costs. 7 When comparing treatments by family costs or health care costs, the treatments are not necessarily cost effective by both perspectives 6 as seen in the study by Kurre et al. 39 Because of the enormous disparity between the impacts on a family versus the health care system, consideration should be given to consistent inclusion of family costs in EE but evaluating the results separately from direct medical costs.
CONCLUSIONS
The results of this review demonstrate the significant opportunities for EE of treatments of childhood cancer.
Incorporating indirect cost estimations and cost-utility evaluation may balance the health care and family perspectives if methodological issues are overcome. 49 This review demonstrates an imbalance of tumor-directed therapy and supportive therapy evaluations. Tumor-directed treatments predict the toxicities encountered and needs for supportive therapies and likely have the largest economic impact. Pediatric oncology has made survival improvements through prospective clinical trials performed in collaborative networks. Applying EE tools to tumordirected therapies in a systematic and objective manner in collaboration within these networks could lead to more efficient use of limited resources.
